This is a randomized, active-controlled, open-label study of pembrolizumab (Pembro) given
prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or
without cisplatin), as post-surgical therapy in treatment nave participants with newly
diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell
carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1
(PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab
given before surgery and after surgery in combination with radiotherapy (with or without
cisplatin) improves major pathological response and event-free survival compared to
radiotherapy (with or without cisplatin) given after surgery alone.
head and neck cancer,
head and neck neoplasms,
head and neck tumor
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.